Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
31053601
DOI
10.1158/1078-0432.ccr-18-3270
PII: 1078-0432.CCR-18-3270
Knihovny.cz E-resources
- MeSH
- Killer Cells, Natural immunology pathology MeSH
- Cyclophosphamide administration & dosage MeSH
- Lymphoma, Large B-Cell, Diffuse blood drug therapy immunology pathology MeSH
- Doxorubicin administration & dosage MeSH
- Lymphoma, Follicular blood drug therapy immunology pathology MeSH
- Antibodies, Monoclonal, Humanized administration & dosage MeSH
- Immunotherapy MeSH
- Humans MeSH
- Survival Rate MeSH
- Prednisone administration & dosage MeSH
- Prognosis MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Rituximab administration & dosage MeSH
- Aged MeSH
- Vincristine administration & dosage MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Antibodies, Monoclonal, Humanized MeSH
- obinutuzumab MeSH Browser
- Prednisone MeSH
- Rituximab MeSH
- Vincristine MeSH
PURPOSE: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with worse outcome in patients receiving antibody-based therapy. PATIENTS AND METHODS: Baseline peripheral blood NKCC was assessed by flow cytometry (CD3-CD56+ and/or CD16+ cells) in 1,064 of 1,202 patients with follicular lymphoma treated with obinutuzumab or rituximab plus chemotherapy in the phase III GALLIUM trial (NCT01332968) and 1,287 of 1,418 patients with diffuse large B-cell lymphoma (DLBCL) treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP or R-CHOP) in the phase III GOYA trial (NCT01287741). The prognostic value of tumor NK-cell gene expression, as assessed by whole-transcriptome gene expression using TruSeq RNA sequencing, was also analyzed. The association of baseline variables, such as treatment arm, was evaluated using multivariate Cox regression models using a stepwise approach. RESULTS: In this exploratory analysis, low baseline peripheral blood NKCC was associated with shorter progression-free survival (PFS) in both follicular lymphoma [hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.02-2.14; P = 0.04] and DLBCL (HR, 1.36; 95% CI, 1.01-1.83; P = 0.04), and overall survival in follicular lymphoma (HR, 2.20; 95% CI, 1.26-3.86; P = 0.0058). Low tumor NK-cell gene expression was associated with shorter PFS in G-CHOP-treated patients with DLBCL (HR, 1.95; 95% CI, 1.22-3.15; P < 0.01). CONCLUSIONS: These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy.
A O U Citta' Della Salute e della Scienza S C Ematologia Turin Italy
Center of Integrated Oncology Cologne Bonn University Hospital Cologne Cologne Germany
Charles University General Hospital Prague Czech Republic
F Hoffmann La Roche Ltd Basel Switzerland
Genentech Inc South San Francisco California
Imperial College London London United Kingdom
Institute of Pathological Physiology Charles University Prague Czech Republic
Kings College Hospital London United Kingdom
References provided by Crossref.org
ClinicalTrials.gov
NCT01332968, NCT01287741
